<article article-type="case-report" dtd-version="1.4" xml:lang="en"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">BMC Infect Dis</journal-id><journal-id journal-id-type="pmc-domain-id">36</journal-id><journal-id journal-id-type="pmc-domain">bmcid</journal-id><journal-title-group><journal-title>BMC Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">1471-2334</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12930593</article-id><article-id pub-id-type="pmcid-ver">PMC12930593.1</article-id><article-id pub-id-type="pmcaid">12930593</article-id><article-id pub-id-type="pmcaiid">12930593</article-id><article-id pub-id-type="pmid">41618183</article-id><article-id pub-id-type="doi">10.1186/s12879-026-12663-6</article-id><article-id pub-id-type="publisher-id">12663</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Successful treatment of pre-extensively drug-resistant tuberculous meningoencephalomyelitis in pregnancy with a bedaquiline and delamanid-based regimen: a case report</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Nie</surname><given-names initials="Q">Qi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yuan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Xiao</surname><given-names initials="F">Fan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="Y">Yong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fu</surname><given-names initials="T">Tingting</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zheng</surname><given-names initials="L">Lijuan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="D">Dongmei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tang</surname><given-names initials="Q">Qiuping</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Liu</surname><given-names initials="T">Ting</given-names></name><address><email>534629003@qq.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Tao</surname><given-names initials="L">Lixuan</given-names></name><address><email>103874586@qq.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00p991c53</institution-id><institution-id institution-id-type="GRID">grid.33199.31</institution-id><institution-id institution-id-type="ISNI">0000 0004 0368 7223</institution-id><institution>Department of Drug-Resistant Tuberculosis, Wuhan Jinyintan Hospital, </institution><institution>Tongji Medical College of Huazhong University of Science and Technology, </institution></institution-wrap>Wuhan, Hubei China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00p991c53</institution-id><institution-id institution-id-type="GRID">grid.33199.31</institution-id><institution-id institution-id-type="ISNI">0000 0004 0368 7223</institution-id><institution>Department of Clinical Laboratory, Wuhan Jinyintan Hospital, </institution><institution>Tongji Medical College of Huazhong University of Science and Technology, </institution></institution-wrap>Wuhan, Hubei China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00e4hrk88</institution-id><institution-id institution-id-type="GRID">grid.412787.f</institution-id><institution-id institution-id-type="ISNI">0000 0000 9868 173X</institution-id><institution>Emergency Department, Puren Hospital, </institution><institution>Wuhan University of Science and Technology, </institution></institution-wrap>Wuhan, Hubei China </aff></contrib-group><pub-date pub-type="epub"><day>30</day><month>1</month><year>2026</year></pub-date><pub-date pub-type="collection"><year>2026</year></pub-date><volume>26</volume><issue-id pub-id-type="pmc-issue-id">503805</issue-id><elocation-id>450</elocation-id><history><date date-type="received"><day>22</day><month>10</month><year>2025</year></date><date date-type="accepted"><day>19</day><month>1</month><year>2026</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>01</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>25</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-25 10:25:14.513"><day>25</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>© The Author(s) 2026</copyright-statement><copyright-year>2026</copyright-year><license><ali:license_ref content-type="ccbyncndlicense" specific-use="textmining" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" xmlns:xlink="http://www.w3.org/1999/xlink">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="12879_2026_Article_12663.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><abstract abstract-type="structured" id="Abs1"><sec><title>Background</title><p id="Par1">Management of pre-extensively drug-resistant tuberculosis (pre-XDR-TB) during pregnancy poses a formidable clinical challenge, particularly when complicated by tuberculous meningoencephalomyelitis (TBMEM), While the WHO operational handbook provides a general framework for drug-resistant TB, robust evidence and specific guidelines for managing severe CNS involvement in pregnancy remain limited.</p></sec><sec><title>Case presentation</title><p id="Par2">We report the successful outcome for a mother and infant in an extremely high-risk case. The patient, at 17 + 6 weeks of gestation following in vitro fertilization (IVF), was diagnosed with pre-XDR-TB. Hematogenous dissemination was confirmed by chest CT showing diffuse miliary nodules, and spinal MRI confirmed meningoencephalomyelitis. Her clinical course was complicated by life-threatening conditions, including TB-associated sepsis (TB-Sepsis) and severe neurological immune reconstitution inflammatory syndrome (Neuro-IRIS) presenting as an intracranial hypertensive crisis. An individualized, multidisciplinary approach centered on a bedaquiline (Bdq) and delamanid (Dlm)-based regimen was implemented. The patient’s condition was effectively controlled, and she delivered a healthy female infant at 35 + 1 weeks of gestation. Both mother and infant recovered well.</p></sec><sec><title>Conclusions</title><p id="Par3">This case demonstrates that a carefully monitored Bdq/Dlm-based regimen can be a life-saving option for severe DR-TB in pregnancy. It also underscores the critical need for systematic TB screening prior to assisted reproductive technology (ART) in high-burden regions.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Pre-extensively drug-resistant tuberculosis (pre-XDR-TB)</kwd><kwd>Tuberculous meningoencephalomyelitis (TBMEM)</kwd><kwd>Pregnancy</kwd><kwd>Bedaquiline</kwd><kwd>Delamanid</kwd><kwd>Immune reconstitution inflammatory syndrome (IRIS)</kwd></kwd-group><funding-group><award-group><funding-source><institution>Health Commission of Hubei Province Program</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© BioMed Central Ltd., part of Springer Nature 2026</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par4">Managing drug-resistant tuberculosis (DR-TB) during pregnancy presents a significant clinical challenge, particularly for severe forms like pre-extensively drug-resistant tuberculous meningoencephalomyelitis (pre-XDR-TBMEM), where evidence for safe and effective treatment is scarce [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The selection of anti-TB drugs is substantially complicated by concerns over potential teratogenicity, often leading to treatment delays or suboptimal regimens that jeopardize both maternal and fetal outcomes. The use of newer drugs, such as bedaquiline (Bdq) and delamanid (Dlm), has revolutionized DR-TB treatment. However, while the WHO Operational Handbook on Tuberculosis (2022 Update) provides guidance on using Bedaquiline and Delamanid during pregnancy [<xref ref-type="bibr" rid="CR3">3</xref>], robust evidence and specific protocols for managing pre-XDR-TBMEM (involving the central nervous system) remain limited and largely rely on observational data [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par5">Here, we present an exceptionally complex case of a mid-trimester pregnant woman with pre-XDR-TBMEM, further complicated by TB-Sepsis and neurological immune reconstitution inflammatory syndrome (Neuro-IRIS). This report details the successful use of an individualized, Bdq/Dlm-based regimen within a multidisciplinary framework, which ultimately led to favorable outcomes for both mother and infant. It offers crucial insights into managing such critically ill patients, where the benefits of aggressive treatment must be weighed against potential fetal risks.</p></sec><sec id="Sec2"><title>Case presentation</title><p id="Par6"><bold>Patient Information</bold>: A 33-year-old female at 17 + 6 weeks of gestation (conceived via IVF-ET) was transferred to our hospital on September 26, 2024. <bold>Medical Profile</bold>: The patient had no history of HIV infection, diabetes mellitus, or autoimmune diseases. Her immunocompromised state was attributed to the physiological immune modulation of pregnancy. <bold>Past Medical History</bold>: She had a history of tuberculous pleurisy in 2018 (treated with 2HRZE/6HR but self-discontinued after 8 months without bacteriological confirmation) and recurrent pleurisy in 2020 (diagnosed clinically at a local hospital; treated with FDC-HRZE for one year). Crucially, as no pathogen was isolated, drug susceptibility testing (DST) could not be performed during these episodes.She underwent IVF-ET on June 12, 2024, due to fallopian tube blockage. Notably, despite her TB history, no specific TB screening (e.g., Chest X-ray or Interferon-Gamma Release Assay) was performed prior to IVF.</p><p id="Par7"><bold>Clinical Findings &amp; Diagnosis</bold>: On admission, vital signs showed tachycardia (127 bpm) but no hypotension. Neurological exam revealed nuchal rigidity and asymmetric limb weakness. <bold>Laboratory Findings (Reference ranges provided)</bold>: Initial CSF analysis showed significantly elevated pressure &gt; 330 mmH₂O (Ref: 70–200), nucleated cell count 340 × 10⁶/L (Ref: 0–5), glucose 0.75 mmol/L (Ref: 2.5–4.5), and protein 3147 mg/L (Ref: 150–450). <bold>Diagnostic Confirmation</bold>: On September 28, Targeted Next-Generation Sequencing (tNGS) (Platform: FASTASeq 300; Database: CARD v2.0.0) of the CSF confirmed Mycobacterium tuberculosis resistant to isoniazid, rifampicin, pyrazinamide, ethambutol, and fluoroquinolones. <bold>Diagnosis</bold>: The patient was diagnosed with pre-XDR-TB (defined as MDR/RR-TB with additional resistance to any fluoroquinolone, according to the WHO 2021 update). <bold>Culture Results</bold>: MGIT 960 liquid cultures for blood, sputum, and CSF were consistently negative, likely due to prior empirical anti-TB treatment received at the local hospital.</p></sec><sec id="Sec3"><title>Treatment course (See Table <xref ref-type="table" rid="Tab1">1</xref> for detailed timeline)</title><p id="Par8">
<table-wrap id="Tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Timeline of clinical events, diagnostic findings, and therapeutic interventions</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Time (Days from Adm.)</th><th align="left" colspan="1" rowspan="1">Date</th><th align="left" colspan="1" rowspan="1">Key clinical events &amp; diagnostics</th><th align="left" colspan="1" rowspan="1">Anti-TB regimen (Dosage &amp; route)</th><th align="left" colspan="1" rowspan="1">Adjunctive therapy &amp; management</th><th align="left" colspan="1" rowspan="1">Rationale for adjustment</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>Day 1</bold>
</td><td align="char" char="−" colspan="1" rowspan="1">2024-09-26</td><td align="left" colspan="1" rowspan="1"><bold>Admission</bold> Severe headache, somnolence. <bold>ICP</bold>: &gt;330 mmH₂O <bold>Dx</bold>: GeneXpert (+) for RR-TB</td><td align="left" colspan="1" rowspan="1"><bold>Empirical Regimen</bold>: Mfx (0.4 g qd), Lzd (600 mg qd), Mpm (1.0 g q8h)ᵃ, Am (0.6 g qd), H (0.6 g qd), Z (1.5 g qd)</td><td align="left" colspan="1" rowspan="1"><bold>Steroids</bold>: Dexamethasone 10 mg/d IV <bold>ICP Control</bold>: Mannitol 250 mL q6h</td><td align="left" colspan="1" rowspan="1">Empirical coverage for RR-TBM pending comprehensive DST.</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Day 3</bold>
</td><td align="char" char="−" colspan="1" rowspan="1">2024-09-28</td><td align="left" colspan="1" rowspan="1"><bold>Diagnosis Refined: Pre-XDR-TB</bold> tNGS: Resistant to H, R, Z, E + Fluoroquinolones. Culture: Negative (MGIT 960)ᵇ</td><td align="left" colspan="1" rowspan="1"><bold>Stop</bold>: Mfx, H, Z <bold>Start: Bdq</bold> (400 mg qd)ᶜ, <bold>Cs</bold> (250 mg am/500 mg pm)</td><td align="left" colspan="1" rowspan="1">Same as above.</td><td align="left" colspan="1" rowspan="1">Adjusted based on molecular DST showing FQ-resistance.</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Day 6</bold>
</td><td align="char" char="−" colspan="1" rowspan="1">2024-10-01</td><td align="left" colspan="1" rowspan="1"><bold>Adverse Event (CNS)</bold> Dizziness, sleep disturbance.</td><td align="left" colspan="1" rowspan="1"><bold>Stop</bold>: Cs <bold>Start: Dlm</bold> (100 mg bid)</td><td align="left" colspan="1" rowspan="1">Same as above.</td><td align="left" colspan="1" rowspan="1">Suspected Cs-related CNS toxicity; switched to Dlm.</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Day 8</bold>
</td><td align="char" char="−" colspan="1" rowspan="1">2024-10-03</td><td align="left" colspan="1" rowspan="1"><p><bold>TB-Sepsis &amp; Organ Failure</bold> SOFA score: 5 ALT: 169→213 U/L; Cr: 146 µmol/L PCT: 0.31 ng/mL</p><p>eGFR40.46 mL/min/1.73 m²</p></td><td align="left" colspan="1" rowspan="1"><bold>Hold</bold>: Bdq, Am (toxic) <bold>Continue</bold>: Dlm, Lzd, Mpmᵃ</td><td align="left" colspan="1" rowspan="1"><bold>ICU Transfer</bold> Stop Mannitol (renal risk); Switch to Glycerol-fructose. Liver protection therapy.</td><td align="left" colspan="1" rowspan="1">Sepsis-induced multi-organ dysfunction. Potentially hepatotoxic/nephrotoxic drugs withheld.</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Day 13</bold>
</td><td align="char" char="−" colspan="1" rowspan="1">2024-10-08</td><td align="left" colspan="1" rowspan="1"><bold>Stabilization</bold> Consciousness improved. Liver/Renal function recovering.</td><td align="left" colspan="1" rowspan="1"><bold>Continue</bold>: Dlm, Lzd, Mpmᵃ</td><td align="left" colspan="1" rowspan="1">Transferred out of ICU.</td><td align="left" colspan="1" rowspan="1">Clinical improvement.</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Day 20</bold>
</td><td align="char" char="−" colspan="1" rowspan="1">2024-10-15</td><td align="left" colspan="1" rowspan="1"><bold>Disease Extent Confirmed</bold> Chest CT: Miliary TB ICP: 250 mmH₂O</td><td align="left" colspan="1" rowspan="1"><bold>Restart: Bdq</bold> (200 mg tiw) Regimen: Bdq + Dlm + Lzd + Mpmᵃ</td><td align="left" colspan="1" rowspan="1">Add: Clopidogrel (for new lacunar infarction).</td><td align="left" colspan="1" rowspan="1">Liver function normalized; regimen re-intensified.</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Day 29</bold>
</td><td align="char" char="−" colspan="1" rowspan="1">2024-10-24</td><td align="left" colspan="1" rowspan="1"><bold>Symptom Fluctuation</bold> Intermittent fever, ICP 300 mmH₂O.</td><td align="left" colspan="1" rowspan="1"><bold>Restart: Cs</bold> (750 mg/d) Regimen: Bdq + Dlm + Lzd + Mpmᵃ + Cs</td><td align="left" colspan="1" rowspan="1">Increase Mannitol freq.</td><td align="left" colspan="1" rowspan="1">Intensification due to insufficient ICP control.</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Day 35</bold>
</td><td align="char" char="−" colspan="1" rowspan="1">2024-10-30</td><td align="left" colspan="1" rowspan="1"><bold>Neuro-IRIS Crisis ICP peak: 480 mmH₂O</bold> Worsening headache/fever.</td><td align="left" colspan="1" rowspan="1"><bold>Maintain</bold>: Full Regimen (Bdq + Dlm + Lzd + Mpmᵃ + Cs)</td><td align="left" colspan="1" rowspan="1"><bold>Aggressive IRIS Mgmt</bold>: Freq. Lumbar punctures + Intrathecal Dexamethasone (5 mg/dose).</td><td align="left" colspan="1" rowspan="1">Paradoxical reaction (IRIS) diagnosed. Regimen maintained; anti-inflammatory therapy escalated.</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Day 43</bold>
</td><td align="char" char="−" colspan="1" rowspan="1">2024-11-07</td><td align="left" colspan="1" rowspan="1"><bold>IRIS Controlled</bold> ICP decreasing, symptoms resolved.</td><td align="left" colspan="1" rowspan="1"><bold>Maintain</bold>: Full Regimen</td><td align="left" colspan="1" rowspan="1"><bold>Steroid Tapering</bold>: Switch to Oral Prednisone.</td><td align="left" colspan="1" rowspan="1">IRIS phase subsided.</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Day 122</bold>
</td><td align="char" char="−" colspan="1" rowspan="1">2025-01-25</td><td align="left" colspan="1" rowspan="1"><bold>Delivery</bold> 35 + 1 weeks gestation.</td><td align="left" colspan="1" rowspan="1"><bold>Maintain</bold>: Full Regimen</td><td align="left" colspan="1" rowspan="1"><bold>C-Section</bold> Infant: 1850 g, no TB infection.</td><td align="left" colspan="1" rowspan="1">Multidisciplinary decision for delivery.</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Month 6</bold>
</td><td align="char" char="−" colspan="1" rowspan="1">2025-03</td><td align="left" colspan="1" rowspan="1"><bold>Follow-up/Toxicity</bold> Hyperlactatemia (Lac 3.5 mmol/L).</td><td align="left" colspan="1" rowspan="1"><bold>Adjust Lzd</bold>: Reduced to 300 mg/d. <bold>Stop Mpm</bold>: Discontinued after 6 months.</td><td align="left" colspan="1" rowspan="1"><bold>Outcome</bold>: Mother: Full neuro-recovery. Infant: Healthy.</td><td align="left" colspan="1" rowspan="1">Lzd dose reduced due to mitochondrial toxicity; Mpm stopped after intensive phase.</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: Adm: admission; ICP: intracranial pressure; RR-TB: rifampicin-resistant tuberculosis; tNGS: targeted next-generation sequencing; Mfx: moxifloxacin; Lzd: linezolid; Mpm: meropenem; Am: amikacin; H: isoniazid; Z: pyrazinamide; Bdq: bedaquiline; Cs: cycloserine; Dlm: delamanid</p><p>a. Meropenem Administration: Meropenem (1.0 g IV q8h) was administered in combination with oral Amoxicillin-Clavulanate (125 mg) given 30 min prior to each infusion to inhibit beta-lactamase degradation, as per carbapenem-containing TB regimens</p><p>b. Culture Results: MGIT 960 liquid cultures for blood, sputum, and CSF were consistently negative throughout the course, likely due to prior empirical anti-TB treatment received at the local hospital before transfer. Diagnosis and resistance profiling relied on GeneXpert and tNGS</p><p>c. Bedaquiline Dosing: Administered as a loading dose of 400 mg daily for the first 2 weeks, followed by 200 mg three times per week (tiw)</p></table-wrap-foot></table-wrap>
</p><p id="Par9"><bold>Phase 1: Induction &amp; Adjustment (Day 1–7)</bold>: Empirical therapy consisting of Mfx, Lzd, Mpm, Am, H, and Z was initiated on admission. Given the patient’s impaired consciousness (requiring nasogastric feeding) and the critical need for rapid bactericidal activity, an intravenous-based regimen was prioritized to ensure reliable bioavailability. This combination provided at least three effective agents (Lzd, Am, Mpm), as local epidemiological data in Hubei Province indicates extremely low resistance rates to these drugs. Although Bedaquiline (Bdq) is a core drug, it is currently only available in oral formulation. Therefore, its initiation was deferred pending the tNGS results (expected within 48 h) to confirm the resistance profile. On Day 3 (September 28), following the confirmation of FQ-resistance via tNGS, Mfx was immediately discontinued and replaced by Bdq to construct an effective pre-XDR regimen.</p><p id="Par10"><bold>Phase 2: TB-Sepsis &amp; ICU Care (Day 8–12)</bold>: On October 3, the patient developed somnolence, tachypnea, and tachycardia. Laboratory results revealed multi-organ dysfunction: acute hepatic injury (ALT 169 U/L, AST 61 U/L; later peaking at 213 U/L and 130 U/L, respectively), renal impairment (BUN 12.74 mmol/L [Ref: 2.6–7.5], Cr 146 µmol/L [Ref: 41–73], and eGFR declined to 40.46 mL/min/1.73 m² [Ref: &gt;90]), and myocardial injury (CK-MB max 28 U/L, LDH max 339 U/L). Coupled with elevated inflammatory markers (Procalcitonin 0.31 ng/mL; CRP 31.6 mg/L) and a SOFA score of 5, TB-Sepsis was diagnosed. The elevated PCT and CRP differentiated this systemic inflammatory response from pure drug-induced liver injury (DILI). Potentially toxic drugs (Bdq, Am) were withheld. She stabilized after 5 days in ICU.</p><p id="Par11"><bold>Phase 3: Disease Extent Confirmation &amp; Regimen Optimization (Day 18+)</bold>: Bedaquiline was reintroduced on October 13 (Day 18). On October 15 (Day 20), a chest CT scan (performed following stabilization, as earlier transport was precluded by her critical instability) revealed diffuse miliary nodules in both lungs (Fig. <xref ref-type="fig" rid="Fig1">1</xref>A), confirming hematogenous dissemination.The anti-TB regimen was optimized to Bedaquiline (400 mg qd for 2 weeks, then 200 mg tiw), Delamanid (100 mg bid), Linezolid (600 mg qd), and Meropenem (1.0 g q8h). Meropenem was administered with oral Amoxicillin-Clavulanate to inhibit beta-lactamase.</p><p id="Par12">
<fig id="Fig1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Imaging evidence of disseminated tuberculosis and spinal involvement. (<bold>A</bold>) Chest CT scans (two representative slices) taken on October 15, 2024 (Day 20), showing diffuse miliary nodules distributed throughout both lungs (arrows), confirming hematogenous dissemination. (<bold>B</bold>) Contrast-enhanced MRI of the cervicothoracic junction (November 13, 2024) and (<bold>C</bold>) the lumbar spine (November 18, 2024), revealing linear meningeal enhancement along the spinal cord (arrows). These findings objectively support the diagnosis of tuberculous meningoencephalomyelitis</p></caption><graphic id="d33e668" orientation="portrait" position="float" xlink:href="12879_2026_12663_Fig1_HTML.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig>
</p><p id="Par13"><bold>Phase 4: Neuro-IRIS Crisis (Day 35)</bold>: On October 30, the patient developed severe headache and fever. ICP spiked to 480 mmH₂O. This was diagnosed as Neuro-IRIS. The anti-TB regimen was maintained. IRIS was managed with frequent CSF drainage and intrathecal dexamethasone injections (5 mg/dose). <bold>Spinal Involvement</bold>: Subsequent MRI of the spine (November 13 &amp; 18) revealed linear meningeal enhancement along the cervical, thoracic, and lumbar spinal cord (Fig. <xref ref-type="fig" rid="Fig1">1</xref>B and C), objectively confirming the diagnosis of meningoencephalomyelitis.</p><p id="Par14"><bold>Maternal and Infant Outcome</bold>: The patient underwent a cesarean section on January 25, 2025 (35 + 1 weeks). <bold>Neonate Assessment</bold>: The infant weighed 1,850 g. Placental pathology showed no evidence of granulomas or caseous necrosis. The neonate’s sputum culture (Day 1, 7) and T-SPOT.TB test (Day 1, 10) were negative. <bold>Follow-up</bold>: Serial brain MRI (Fig. <xref ref-type="fig" rid="Fig2">2</xref>) showed resolution of meningeal enhancement. The mother is scheduled for a total treatment duration of 18–20 months.</p><p id="Par15">
<fig id="Fig2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Serial Brain MRI scans demonstrating disease evolution. Columns represent time points: (<bold>A</bold>) October 15, 2024 (Initial assessment); (<bold>B</bold>) November 12, 2024 (During Neuro-IRIS crisis); (<bold>C</bold>) January 10, 2025 (Recovery). Note the extensive basal meningeal enhancement (white arrows) which paradoxically worsened in November (<bold>B</bold>) despite effective treatment, consistent with Neuro-IRIS, before resolving significantly in January (<bold>C</bold>)</p></caption><graphic id="d33e717" orientation="portrait" position="float" xlink:href="12879_2026_12663_Fig2_HTML.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig>
</p></sec><sec id="Sec4"><title>Discussion and conclusions</title><p id="Par16">This case highlights several critical management principles for extremely severe DR-TB in pregnancy. First, the successful navigation of two distinct life-threatening complications—TB-Sepsis and Neuro-IRIS—underscores the importance of dynamic clinical monitoring. The initial deterioration was attributed to TB-Sepsis, a severe systemic inflammatory response to a high bacillary load [<xref ref-type="bibr" rid="CR6">6</xref>]. Crucially, this diagnosis was objectively supported by a SOFA score of 5 and significantly elevated procalcitonin (0.31 ng/mL), distinguishing it from drug toxicity, while diffuse miliary nodules on chest CT (Fig. <xref ref-type="fig" rid="Fig1">1</xref>A) confirmed hematogenous dissemination. In contrast, the later neurological worsening, occurring after initiation of effective therapy, was characteristic of paradoxical Neuro-IRIS, an aberrant immune response that required modulation with intensified corticosteroid therapy [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Differentiating these two syndromes was crucial for tailoring appropriate management.</p><p id="Par17">Second, this case provides vital real-world evidence supporting the use of a Bdq/Dlm-based regimen for life-threatening DR-TB during pregnancy. While safety data for these newer agents are still emerging, the WHO Operational Handbook (2022 Update) outlines their potential utility in MDR-TB regimens [<xref ref-type="bibr" rid="CR3">3</xref>] and the maternal mortality risk of untreated pre-XDR-TBMEM is exceedingly high [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Following extensive counseling and informed consent, a decision was made to prioritize maternal survival. Our experience aligns with recent findings suggesting that in severe cases, the benefits of Bdq-containing regimens likely outweigh the theoretical fetal risks, and good neonatal outcomes are achievable with close monitoring [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par18">Finally, the patient’s history of recurrent TB and conception via IVF-ET without prior TB screening (specifically Chest X-ray or Interferon-Gamma Release Assay [IGRA]) highlights a significant gap in care. Genital TB is a known, often occult, cause of infertility (likely implicated in this patient’s tubal obstruction), and the immunological shifts during pregnancy can reactivate latent infection [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. This case argues strongly for incorporating systematic screening for both active and latent TB into pre-ART protocols, especially in high-burden settings.</p><p id="Par19">In conclusion, this case demonstrates that with an individualized, multidisciplinary approach, it is possible to save both mother and infant in the face of pre-XDR-TBMEM with catastrophic complications during pregnancy. This provides an important reference for managing similar extreme cases and contributes crucial evidence for evolving global treatment guidelines.</p></sec></body><back><fn-group><fn><p><bold>Publisher’s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Qi Nie, Yuan Liu and Fan Xiao contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Q.N., Y.L. and F.X. contributed to the clinical management of the patient, data collection, and wrote the initial draft of the manuscript. Y.Z., T.F., L.Z., D.H., and Q.T. were involved in the multidisciplinary treatment and patient care. T.L. and L.T. conceived the study, supervised the project, and critically revised the manuscript. All authors have read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by the Health Commission of Hubei Province Program (to Q.N.).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par20">The study was approved by the Medical Ethics Committee of Wuhan Jinyintan Hospital (Approval No. Shen KY-2024-30.01). Written informed consent to participate was obtained from the patient.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par21">Written informed consent for publication of their clinical details and/or clinical images was obtained from the patient. A copy of the consent form is available for review by the Editor of this journal.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par22">The authors declare no competing interests.</p></notes></notes><glossary><title>Abbreviations</title><def-list><def-item><term>pre-XDR-TB</term><def><p id="Par23">Pre-extensively drug-resistant tuberculosis</p></def></def-item><def-item><term>TBMEM</term><def><p id="Par24">Tuberculous meningoencephalomyelitis</p></def></def-item><def-item><term>Bdq</term><def><p id="Par25">Bedaquiline</p></def></def-item><def-item><term>Dlm</term><def><p id="Par26">Delamanid</p></def></def-item><def-item><term>Neuro-IRIS</term><def><p id="Par27">Neurological immune reconstitution inflammatory syndrome</p></def></def-item><def-item><term>DR-TB</term><def><p id="Par28">Drug-resistant tuberculosis</p></def></def-item><def-item><term>IVF-ET</term><def><p id="Par29">In-vitro fertilization and embryo transfer</p></def></def-item><def-item><term>CSF</term><def><p id="Par30">Cerebrospinal fluid</p></def></def-item><def-item><term>RR-TB</term><def><p id="Par31">Rifampicin-resistant tuberculosis</p></def></def-item><def-item><term>tNGS</term><def><p id="Par32">Targeted next-generation sequencing</p></def></def-item><def-item><term>Cs</term><def><p id="Par33">Cycloserine</p></def></def-item><def-item><term>SOFA</term><def><p id="Par34">Sequential Organ Failure Assessment</p></def></def-item><def-item><term>ICU</term><def><p id="Par35">Intensive Care Unit</p></def></def-item><def-item><term>ICP</term><def><p id="Par36">Intracranial pressure</p></def></def-item></def-list></glossary><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jonsson</surname><given-names>J</given-names></name><name name-style="western"><surname>Kühlmann-Berenzon</surname><given-names>S</given-names></name><name name-style="western"><surname>Berggren</surname><given-names>I</given-names></name><name name-style="western"><surname>Bruchfeld</surname><given-names>J</given-names></name></person-group><article-title>Increased risk of active tuberculosis during pregnancy and postpartum: a register-based cohort study in Sweden</article-title><source>Eur Respir J</source><year>2020</year><volume>55</volume><issue>5</issue><fpage>1901886</fpage><pub-id pub-id-type="doi">10.1183/13993003.01886-2019</pub-id><pub-id pub-id-type="pmid">31862768</pub-id><pub-id pub-id-type="pmcid">PMC7083553</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Jonsson J, Kühlmann-Berenzon S, Berggren I, Bruchfeld J. Increased risk of active tuberculosis during pregnancy and postpartum: a register-based cohort study in Sweden. Eur Respir J. 2020;55(5):1901886.<pub-id pub-id-type="pmid">31862768</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1183/13993003.01886-2019</pub-id><pub-id pub-id-type="pmcid">PMC7083553</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alene</surname><given-names>KA</given-names></name><name name-style="western"><surname>Murray</surname><given-names>MB</given-names></name><name name-style="western"><surname>Van De Water</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Becerra</surname><given-names>MC</given-names></name><name name-style="western"><surname>Atalell</surname><given-names>KA</given-names></name><name name-style="western"><surname>Nicol</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Treatment outcomes among pregnant patients with multidrug-resistant tuberculosis: a systematic review and meta-analysis</article-title><source>JAMA Netw Open</source><year>2022</year><volume>5</volume><issue>6</issue><fpage>e2216527</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.16527</pub-id><pub-id pub-id-type="pmid">35687333</pub-id><pub-id pub-id-type="pmcid">PMC9187956</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Alene KA, Murray MB, Van De Water BJ, Becerra MC, Atalell KA, Nicol MP, et al. Treatment outcomes among pregnant patients with multidrug-resistant tuberculosis: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(6):e2216527.<pub-id pub-id-type="pmid">35687333</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1001/jamanetworkopen.2022.16527</pub-id><pub-id pub-id-type="pmcid">PMC9187956</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>WHO operational handbook on tuberculosis. Module 4: Treatment - Drug-resistant tuberculosis treatment, 2022 update</source><year>2022</year><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name></element-citation><mixed-citation id="mc-CR3" publication-type="book">World Health Organization. WHO operational handbook on tuberculosis. Module 4: Treatment - Drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022.</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loveday</surname><given-names>M</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>J</given-names></name><name name-style="western"><surname>Sunkari</surname><given-names>B</given-names></name><name name-style="western"><surname>Master</surname><given-names>I</given-names></name><name name-style="western"><surname>Hlangu</surname><given-names>S</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>T</given-names></name><etal/></person-group><article-title>Maternal and infant outcomes among pregnant women treated for multidrug/rifampicin-resistant tuberculosis in South Africa</article-title><source>Clin Infect Dis</source><year>2021</year><volume>72</volume><issue>7</issue><fpage>1158</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa189</pub-id><pub-id pub-id-type="pmid">32141495</pub-id><pub-id pub-id-type="pmcid">PMC8028100</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Loveday M, Hughes J, Sunkari B, Master I, Hlangu S, Reddy T, et al. Maternal and infant outcomes among pregnant women treated for multidrug/rifampicin-resistant tuberculosis in South Africa. Clin Infect Dis. 2021;72(7):1158–68.<pub-id pub-id-type="pmid">32141495</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1093/cid/ciaa189</pub-id><pub-id pub-id-type="pmcid">PMC8028100</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lotia Farrukh</surname><given-names>I</given-names></name><name name-style="western"><surname>Lachenal</surname><given-names>N</given-names></name><name name-style="western"><surname>Adenov</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Pregnancy and birth outcomes in patients with multidrug-resistant tuberculosis treated with regimens that include new and repurposed drugs</article-title><source>Clin Infect Dis</source><year>2024</year><volume>78</volume><issue>1</issue><fpage>144</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/cid/ciad445</pub-id><pub-id pub-id-type="pmid">37606512</pub-id><pub-id pub-id-type="pmcid">PMC10810705</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Lotia Farrukh I, Lachenal N, Adenov MM, et al. Pregnancy and birth outcomes in patients with multidrug-resistant tuberculosis treated with regimens that include new and repurposed drugs. Clin Infect Dis. 2024;78(1):144–8.<pub-id pub-id-type="pmid">37606512</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1093/cid/ciad445</pub-id><pub-id pub-id-type="pmcid">PMC10810705</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caws</surname><given-names>M</given-names></name><name name-style="western"><surname>Torok</surname><given-names>ME</given-names></name><name name-style="western"><surname>D’Arcy Richardson</surname><given-names>M</given-names></name><name name-style="western"><surname>Dheda</surname><given-names>K</given-names></name></person-group><article-title>Sepsis in tuberculosis</article-title><source>Lancet Respir Med</source><year>2021</year><volume>9</volume><issue>7</issue><fpage>711</fpage><lpage>3</lpage></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Caws M, Torok ME, D’Arcy Richardson M, Dheda K. Sepsis in tuberculosis. Lancet Respir Med. 2021;9(7):711–3.</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Toh MR, Tan SSX, Angela T, Ong TH. Diagnostic dilemma of a new endobronchial lesion in a patient on anti-tuberculosis regimen: unveiling tuberculosis immune reconstitution inflammatory syndrome. BMC Infect Dis. 2025;25.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1186/s12879-025-11047-6</pub-id><pub-id pub-id-type="pmcid">PMC12048918</pub-id><pub-id pub-id-type="pmid">40316898</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Starshinova A, Churilov LP, Kudryavtsev I, Rubinstein A, Belyaeva E, Kulpina A, et al. Immune-neuroendocrine reactivity and features of tuberculosis in pregnancy. Front Med. 2025;12.<pub-id assigning-authority="pmc" pub-id-type="doi">10.3389/fmed.2025.1503402</pub-id><pub-id pub-id-type="pmcid">PMC11840263</pub-id><pub-id pub-id-type="pmid">39981081</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Padmapriyadarsini</surname><given-names>C</given-names></name><name name-style="western"><surname>Vohra</surname><given-names>V</given-names></name><name name-style="western"><surname>Bhatnagar</surname><given-names>A</given-names></name><etal/></person-group><article-title>Bedaquiline, delamanid, linezolid, and Clofazimine for treatment of pre-extensively drug-resistant tuberculosis</article-title><source>Clin Infect Dis</source><year>2023</year><volume>76</volume><issue>3</issue><fpage>e938</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1093/cid/ciac528</pub-id><pub-id pub-id-type="pmcid">PMC9907500</pub-id><pub-id pub-id-type="pmid">35767251</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Padmapriyadarsini C, Vohra V, Bhatnagar A, et al. Bedaquiline, delamanid, linezolid, and clofazimine for treatment of pre-extensively drug-resistant tuberculosis. Clin Infect Dis. 2023;76(3):e938–46.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1093/cid/ciac528</pub-id><pub-id pub-id-type="pmcid">PMC9907500</pub-id><pub-id pub-id-type="pmid">35767251</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Court</surname><given-names>R</given-names></name><name name-style="western"><surname>Gausi</surname><given-names>K</given-names></name><name name-style="western"><surname>Mkhize</surname><given-names>B</given-names></name><name name-style="western"><surname>Wiesner</surname><given-names>L</given-names></name><name name-style="western"><surname>Waitt</surname><given-names>C</given-names></name><name name-style="western"><surname>McIlleron</surname><given-names>H</given-names></name><etal/></person-group><article-title>Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin-resistant tuberculosis</article-title><source>Br J Clin Pharmacol</source><year>2022</year><volume>88</volume><issue>8</issue><fpage>3548</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1111/bcp.15380</pub-id><pub-id pub-id-type="pmid">35526837</pub-id><pub-id pub-id-type="pmcid">PMC9296589</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Court R, Gausi K, Mkhize B, Wiesner L, Waitt C, McIlleron H, et al. Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin-resistant tuberculosis. Br J Clin Pharmacol. 2022;88(8):3548–58.<pub-id pub-id-type="pmid">35526837</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/bcp.15380</pub-id><pub-id pub-id-type="pmcid">PMC9296589</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quan</surname><given-names>S</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R</given-names></name><name name-style="western"><surname>Ying</surname><given-names>D</given-names></name><name name-style="western"><surname>Luo</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name></person-group><article-title>Meta-analysis of the adverse effects of drug-resistant tuberculosis drugs on pregnant women and fetuses</article-title><source>China Pharm</source><year>2022</year><volume>33</volume><issue>4</issue><fpage>497</fpage><lpage>502</lpage></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Quan S, Xu R, Ying D, Luo M, Zhang R. Meta-analysis of the adverse effects of drug-resistant tuberculosis drugs on pregnant women and fetuses. China Pharm. 2022;33(4):497–502.</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Tal R, Lawal T, Granger E, Simoni M, Hui P, Buza N, et al. Genital tuberculosis screening at an academic fertility center in the United States. Am J Obstet Gynecol. 2020;223(5):737.e1-737.e10.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.ajog.2020.05.045</pub-id><pub-id pub-id-type="pmid">32497612</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schaaf</surname><given-names>HS</given-names></name><name name-style="western"><surname>Collins</surname><given-names>A</given-names></name><name name-style="western"><surname>Bekker</surname><given-names>A</given-names></name><name name-style="western"><surname>Davies</surname><given-names>PDO</given-names></name></person-group><article-title>Tuberculosis at extremes of age</article-title><source>Respirology</source><year>2010</year><volume>15</volume><issue>5</issue><fpage>747</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1843.2010.01784.x</pub-id><pub-id pub-id-type="pmid">20546192</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Schaaf HS, Collins A, Bekker A, Davies PDO. Tuberculosis at extremes of age. Respirology. 2010;15(5):747–63.<pub-id pub-id-type="pmid">20546192</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/j.1440-1843.2010.01784.x</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>